Even Amid Crisis, Congress Could Take Up Part D Reform

With the federal government consumed by responding to the COVID-19 outbreak, the possibility of Congress passing drug-pricing legislation — once a top priority for the Trump administration — might seem dim. But analysts say it’s very possible that something like an overhaul of the Medicare Part D benefit, upon which there is bipartisan agreement, could still make its way into legislation that federal lawmakers pass in the coming weeks or months to address the ongoing public health crisis.

After days of increasingly tense negotiations, the Trump administration and Senate leaders reached a deal in the early hours of March 25 on a stimulus package worth more than $2 trillion that aims to provide relief for Americans and businesses struggling from the widening economic damage wrought by COVID-19. The COVID-19 pandemic, which as of March 25 caused more than 700 deaths in the U.S., has pummeled the stock market and triggered scores of job losses as many of the country’s most populous cities and states shut down non-essential businesses to slow the virus’ spread.

© 2021 MMIT

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Drug_Benefits_Life_Sciences.jpg
November 23

Will ‘Build Back Better’ Spell Disaster for Pharma Innovation?

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-health-plan-weekly-Wall-Street-Isnt-Sweating-Cignas-Third-Quarter-MLR-Miss.jpg
November 23

Big Three PBMs’ 3Q Results Make Up for Insurer Disappointments

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured_AdobeStock_442155384.jpg
November 23

SCAN Health Opts to Invest in Medication Adherence Tool

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today